PhD in molecular pharmacology, expert in the development of new molecules and their formulations, Dr. Gaudriault has led his entire career in pharmaceutical innovation. It will be a key actor in the development of DEINOVE in its three fields of application.
Download the free guide
Boost your gains
Montpellier, may 23, 2017 (18: 30 CEST) – DEINOVE (Alternext Paris : ALDEI), a biotech company that discovers, develops, and produces compounds with high added value from bacteria rare, especially of the genus Déinocoque, announced that Dr. Georges Gaudriault joined its team as Director of Research and Development, in replacement of Jean-Paul Leonetti, who has returned to the CNRS after 6 years of posting and that DEINOVE thanked him for his contribution.
Georges Gaudriault, PhD, has nearly 20 years of experience in the research and development of drugs. He masters all steps of the value chain, including the regulatory aspects and market access. He has held previously and for 9 years as scientific Director at MedinCell, a biopharmaceutical company specializing in the development of formulations of long-acting drugs.
He has also been scientific Director at ObeTherapy – a start-up biotech specializing in the discovery and development of therapies in the areas of obesity, hypercholesterolemia and type II diabetes, and has contributed to the research of the Curie Institute.
Georges Gaudriault also has a solid experience in the United States, having spent several years as a researcher at the prestigious Salk Institute.
Holder of a phd in molecular pharmacology, Georges Gaudriault is also a graduate in molecular biology and biochemistry. He is the author of several patents and numerous publications.
“We are very pleased with the arrival of Georges Gaudriault in our team. His experience in the field of management of projects, formulations and innovative technologies, perfectly meets the needs today are those of DEINOVE in its three fields of application : health, nutrition and cosmetics. Dr. Gaudriault will have the mission to guide our innovation strategy and structure, and manager of our technology platforms and their evolutions. It will thus be a key actor of our development and our partnership strategy, ” said Emmanuel Petiot, ceo of DEINOVE.
Georges Gaudriault adds : “to Transform knowledge and innovation into strategic opportunities and industrial has always been my passion. I am delighted of this new challenge which will allow me to leverage my experience in the discovery and optimization of new molecules but also everything that is related to the structuring of the commercial development, regulatory processes and intellectual property.”
ABOUT DEINOVE
DEINOVE (Alternext Paris : ALDEI) is a biotechnology company that discovers, develops, and produces compounds of industrial interest from microorganisms, only a few for the areas of health, nutrition and cosmetics.
To do this, DEINOVE relies on two key strengths :
A company’s microbial collection, unique in the world of 6 000 bacteria rare, and as yet unexploited, mainly of the genus Deinococcus ;
A platform for engineering genetic, metabolic, and fermentative owner that allows him to transform to how these micro-factories natural new industry standards.
Based in Montpellier, france, DEINOVE currently employs approximately 50 employees and has filed more than 160 patents to the international. The Company is listed on Alternext since April 2010.
Download the free guide
Boost your gains
